Congenital Thrombotic thrombocytopenic purpura (cTTP) research hub

A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)

This study is looking at the long-term safety and helpfulness of a medicine called TAK-755 for people with a rare blood disorder called congenital TTP. It also checks how well TAK-755 prevents TTP episodes in those taking it regularly.